Kamada (KMDA) Total Non-Current Liabilities (2012 - 2026)

Kamada (KMDA) posted quarterly Total Non-Current Liabilities of $63.9 million for Q1 2026, down 3.39% year-on-year from $66.1 million in Q1 2025, and up 2.59% on a QoQ basis from $62.2 million in Q4 2025.

Kamada (KMDA) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends

Kamada (KMDA) has reported Total Non-Current Liabilities for 13 consecutive years, with $63.9 million the latest figure, recorded in Q1 2026.

  • Quarterly Total Non-Current Liabilities fell 3.39% year-over-year to $63.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $63.9 million (down 3.39% YoY) and the FY2025 annual result came in at $62.2 million, down 1.82% from the prior year.
  • Total Non-Current Liabilities improved to $63.9 million in Q1 2026 per KMDA's latest filing, from $62.2 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for KMDA reached as high as $85.7 million in Q1 2022 and fell as low as -$1.8 million in Q1 2023.
  • A 5-year average of $55.0 million and a median of $62.4 million in 2025 frame the typical range for Total Non-Current Liabilities.
  • The largest YoY upside for Total Non-Current Liabilities was 78674.89% in 2023 against a maximum downside of 102.05% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $70.7 million in 2022, then slumped by 96.63% to $2.4 million in 2023, then soared by 2566.19% to $63.4 million in 2024, then decreased by 1.82% to $62.2 million in 2025, then grew by 2.59% to $63.9 million in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $63.9 million, $62.2 million, and $64.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 14.92 Bn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 18.28 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 11.64 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 33.47 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 599.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 20.09 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 1.24 Bn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 6.26 Bn
10 Kamada 401.22 Mn 328.07 Mn 19.12 Mn 63.86 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 63.86 Mn
Dec 31, 2025 62.25 Mn
Sep 30, 2025 64.14 Mn
Jun 30, 2025 62.45 Mn
Mar 31, 2025 66.10 Mn
Dec 31, 2024 63.40 Mn
Sep 30, 2024 61.94 Mn
Jun 30, 2024 58.99 Mn
Mar 31, 2024 59.49 Mn
Dec 31, 2023 2.38 Mn
Sep 30, 2023 61.39 Mn
Jun 30, 2023 71.81 Mn
Mar 31, 2023 -1.76 Mn
Dec 31, 2022 70.65 Mn
Sep 30, 2022 77,936.00
Jun 30, 2022 82.88 Mn
Mar 31, 2022 85.72 Mn
Dec 31, 2021 87.79 Mn
Sep 30, 2021 8.33 Mn
Jun 30, 2021 7.86 Mn